Refine
Departments, institutes and facilities
Document Type
- Article (6)
- Part of a Book (6)
Language
- English (12)
Keywords
- apoptosis (3)
- cell death (3)
- unfolded protein response (3)
- IRE1 (2)
- PERK (2)
- autophagy (2)
- endoplasmic reticulum stress (2)
- ATF4 (1)
- ATF6 (1)
- Adaptation (1)
- Autophagy induction (1)
- Bcl-2 proteins (1)
- Calcium signaling (1)
- Calcium storage (1)
- ER-mitochondria crosstalk (1)
- ERAD (1)
- Endoplasmic reticulum (1)
- Golgi (1)
- Mitochondria associated ER membranes (1)
- Oxidative stress (1)
- Protein folding (1)
- Protein homeostasis (1)
- UPR signaling (1)
- Western blot (1)
- XBP1 (1)
- autophagy signaling pathways (1)
- breast cancer (1)
- carbohydrate metabolism (1)
- caspases (1)
- cell stress (1)
- drug detoxification (1)
- endoplasmic reticulum (ER) stress (1)
- glycosylation (1)
- heat shock proteins (1)
- heat shock response (1)
- intrinsic pathway (1)
- lipid biosynthesis (1)
- membrane trafficking (1)
- physiology (1)
- protein secretion (1)
- qPCR (1)
- real-time PCR (1)
- therapy (1)
- unfolded protein response (UPR) (1)
Triple-negative breast cancer (TNBC) lacks targeted therapies and has a worse prognosis than other breast cancer subtypes, underscoring an urgent need for new therapeutic targets and strategies. IRE1 is an endoplasmic reticulum (ER) stress sensor, whose activation is predominantly linked to the resolution of ER stress and, in the case of severe stress, to cell death. Here we demonstrate that constitutive IRE1 RNase activity contributes to basal production of pro-tumorigenic factors IL-6, IL-8, CXCL1, GM-CSF, and TGFβ2 in TNBC cells. We further show that the chemotherapeutic drug, paclitaxel, enhances IRE1 RNase activity and this contributes to paclitaxel-mediated expansion of tumor-initiating cells. In a xenograft mouse model of TNBC, inhibition of IRE1 RNase activity increases paclitaxel-mediated tumor suppression and delays tumor relapse post therapy. We therefore conclude that inclusion of IRE1 RNase inhibition in therapeutic strategies can enhance the effectiveness of current chemotherapeutics.